Serum Tumor Marker Levels in Rheumatoid Arthritis
Yıl: 2016 Cilt: 49 Sayı: 3 Sayfa Aralığı: 237 - 242 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022
Serum Tumor Marker Levels in Rheumatoid Arthritis
Öz: Giriş ve Amaç: Romatoid Artrit (RA) eklemleri etkileyen ve görece sık rastlanılan inflamatuar bir hastalıktır. Bu çalışmada RA tanılı hastalarda serum tümör belirteçleri olan karsinoembriyonik antijeni (CEA) ,CA 125, CA 19.9 ve CA15.3 düzeylerinin belirlenmesi amaçlanmıştır Yöntem: Bir üniversite hastanesinin romatoloji kliniğinde RA tanısı ile takip edilmekte olan toplam 148 hasta çalışma grubuna ve osteoartrit tanılı 36 hasta ise kontrol grubuna dâhil edilmiştir. Çalışmaya katılan bireylerden alınan kan örneklerinden romatoid faktör (RF), eritrosit sedimantasyon hızı (ESR), anti siklik sitrilünepeptid (anti CCP) ve serum tümör belirteçleri olan CEA,CA19.9,CA 125 ve CA 15.3 düzeyleri ölçülmüştür. Hastalık aktivite skoru çalışmaya dâhil edilme sırasında ilgili romatoloji uzmanı tarafından değerlendirilmiştir. Bulgular: Serum CEA,CA19.9,CA 125 ve CA15.3 düzeyleri RA tanılı hastalarda kontrollere göre anlamlı olarak daha yüksek saptanmıştır. Hem aktif hem de inaktif hasta grubunda tümör belirteç düzeyleri kontrol grubuna göre anlamlı olarak yüksek ölçülmüştür ancak tümör belirteçleri ile hastalık aktivite skoru arasında bir korelasyon saptanamamıştır. Tümör belirteçleri arasında yalnızca CEA ile RF arasında bir korelasyon saptanmıştır(r 0.165, p >0.049). Tartışma ve Sonuç: Serum tümör belirteçleri RA tanılı hastalarda sıklıkla yüksek seviyelerde saptanabilir. Hastaların takibinden sorumlu olan hekimlerin bu durumdan haberdar olmaları, bu hasta grubunda malignite varlığı araştırma amacı ile yapılabilecek olan gereksiz işlemlerin önüne geçilmesine yardımcı olacaktır.
Anahtar Kelime: Konular:
Romatoid Artritli Hastalarda Serum Tümör Belirteçleri Düzeyleri
Öz: Introduction: Rheumatoid arthritis (RA) is a relatively common inflammatory disease generally affecting the joints. This study aimed to assess the levels of various serum tumors markers; carcinoembryonic antigen (CEA), CA 125, CA 19.9 and CA15.3 in patients with a known diagnosis of RA. Methods: A total of 148 patients who were being followed in the rheumatology clinic of a tertiary academic center with a diagnosis of RA and 36 controls were included in the study group. Measurement of rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), anti CCP and serum tumor markers including CEA, CA 19.9, CA 125, CA 15.3 were made from the blood samples obtained from the participants. Disease activity score at the time of study entry was also evaluated by the attending rheumatologist. Results: Serum levels of CEA, CA19.9, CA 125 and CA 15.3 were found to be significantly higher in RA patients compared to controls. This difference was statistically significant in both patient groups with active and inactive disease compared to the control group. However a correlation between tumor markers and disease activity score was not found. Among tumor markers only serum CEA levels were found to be associated with RF levels (r 0.165, p >0.049) Discussion and Conclusion: Serum tumor markers are frequently elevated in patients with RA and caring physicians should be aware of this phenomenon to avoid the use of unnecessary evaluative procedures for searching presence of malignancy in these group of patients.
Anahtar Kelime: Konular:
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Gerlag DM, Norris JM, Tak PP. RA: from risk factors and pathogenesis to prevention: Towards prevention of autoantibody-positive rheumatoid arthritis: from lifestyle modification to preventive treatment. Rheumatology (Oxford) [Internet]. 2015;kev347.
- 2. Siebert S, Tsoukas A, Robertson J, Mcinnes I. Cytokines as Therapeutic Targets in Rheumatoid Arthritis and Other Inflammatory Diseases. Pharmacol Rev. 2015;67(April):280-309
- 3. Shen R , Ren X, Jing R, Shen X, Chen J, Ju S YC. Rheumatoid Factor, Anti-Cyclic Citrullinated Peptide Antibody, C-Reactive Protein, and Erythrocyte Sedimentation Rate for the Clinical Diagnosis of Rheumatoid Arthritis. Lab Med. 2015;46(3):226-9
- 4. Perkins GL, Slater ED, Sanders GK, Prichard JG. Serum tumor markers. Am Fam Physician. 2003;68(6):1075-82
- 5. Streppel MM, Vincent A, Mukherjee R, Campbell NR, Chen SH, Konstantopoulos K, et al. Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon. Hum Pathol. 2012;43(10):1755- 63
- 6. Kufe DW. MUC1-C Oncoprotein as a Target in Breast Cancer; Activation of Signaling Pathways and Therapeutic Approaches. Oncogene. 2013;32(9):1073-81
- 7. Yue T, Maupin KA, Fallon B, Li L, Partyka K, Anderson MA, et al. Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers. PLoS One. 2011;6(12)
- 8. Ballesta AM, Molina R, Filella X, Jo J GN. Carcinoembryonic antigen in staging and follow-up of patients with solid tumors. Tumour Biol. 1995;16(1):36-41
- 9. Arnett FC, Edworthy SM, Bloch D a, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-24
- 10. Kashiwabara K, Nakamura H, Kiguchi T, Yagyu H, Kishi K MK. Carcinoembryonic antigen and neutrophils in healthy smokers. Nihon Kyobu Shikkan Gakkai Zasshi. 1997;35(2):154-9
- 11. Strange A, Capon F, Spencer CC, Knight J, Weale ME, Allen MH, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet [Internet]. 2010/10/19 ed. 2010;42(11):985-90
- 12. Szekanecz E, Sandor Z, Antal-Szalmas P, Soos L, Lakos G, Besenyei T, et al. Increased production of the soluble tumor-associated antigens CA19-9, CA125, and CA15-3 in rheumatoid arthritis: Potential adhesion molecules in synovial inflammation? In: Annals of the New York Academy of Sciences. 2007. p. 359-71
- 13. Unger A, Panayi GS LM. Carcinoembryonic antigen in rheumatoid arthritis. Lancet. 1974;1:791-3
- 14. Ganguly A, Yeltsin E, Robbins J. Identification of a carcinoembryonic antigen binding protein on monocytes. In: Biochemical and Biophysical Research Communications. 2003. p. 319-23
- 15. Aarons CB, Bajenova O, Andrews C, Heydrick S, Bushell KN, Reed KL, et al. Carcinoembryonic antigen-stimulated THP-1 macrophages activate endothelial cells and increase cell-cell adhesion of colorectal cancer cells. Clin Exp Metastasis. 2007;24(3):201-9
- 16. Rump A, Morikawa Y, Tanaka M, Minami S, Umesaki N, Takeuchi M MA. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem. 2004;279(10):9190-8
- 17. Zeillemaker a M, Verbrugh H a, Hoynck van Papendrecht a a, Leguit P. CA 125 secretion by peritoneal mesothelial cells. J Clin Pathol. 1994;47(3):263-5
- 18. Fabris C, Falleti E, Pirisi M, Soardo G, Toniutto P, Vitulli D, Bortolotti N, Gonano F BE. Non-specific increase of serum carbohydrate antigen 19-9 in patients with liver disease associated with increased circulating levels of adhesion molecules. Clin Chim Acta. 1995;243(1):25-33
- 19. Li X, Wang L, Nunes DP, Troxler RF, Offner GD. Pro-inflammatory cytokines up-regulate MUC1 gene expression in oral epithelial cells. J Dent Res [Internet]. 2003;82(11):883-7
- 20. Celeste S, Santaniello A, Caronni M, Franchi J, Severino A, Scorza R, et al. Carbohydrate antigen 15.3 as a serum biomarker of interstitial lung disease in systemic sclerosis patients. Eur J Intern Med. 2013;24(7):671-6
- 21. Dettke M, Pálfi G, Pursch E, Fischer MB, Loibner H. Increased expression of the blood group-related Lewis Y antigen on synovial fluid granulocytes of patients with arthritic joint diseases. Rheumatology (Oxford) [Internet]. 2001;40(9):1033-7
- 22. Koch AE, Burrows JC, Haines GK, Carlos TM, Harlan JM LS. Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteoarthritic synovial tissues. Lab Invest. 1991;64(3):313-20
- 23. Ilantzis C, Demarte L, Screaton RA, Stanners CP. Deregulated Expression of the Human Tumor Marker CEA and CEA Family Member CEACAM6 Disrupts Tissue Architecture and Blocks Colonocyte Differentiatio. Neoplasia. 2002;4(2):151-63
| APA | SEBER S, Solmaz D, YETİŞYİĞİT T (2016). Serum Tumor Marker Levels in Rheumatoid Arthritis. , 237 - 242. |
| Chicago | SEBER SELCUK,Solmaz Dilek,YETİŞYİĞİT Tarkan Serum Tumor Marker Levels in Rheumatoid Arthritis. (2016): 237 - 242. |
| MLA | SEBER SELCUK,Solmaz Dilek,YETİŞYİĞİT Tarkan Serum Tumor Marker Levels in Rheumatoid Arthritis. , 2016, ss.237 - 242. |
| AMA | SEBER S,Solmaz D,YETİŞYİĞİT T Serum Tumor Marker Levels in Rheumatoid Arthritis. . 2016; 237 - 242. |
| Vancouver | SEBER S,Solmaz D,YETİŞYİĞİT T Serum Tumor Marker Levels in Rheumatoid Arthritis. . 2016; 237 - 242. |
| IEEE | SEBER S,Solmaz D,YETİŞYİĞİT T "Serum Tumor Marker Levels in Rheumatoid Arthritis." , ss.237 - 242, 2016. |
| ISNAD | SEBER, SELCUK vd. "Serum Tumor Marker Levels in Rheumatoid Arthritis". (2016), 237-242. |
| APA | SEBER S, Solmaz D, YETİŞYİĞİT T (2016). Serum Tumor Marker Levels in Rheumatoid Arthritis. ACTA ONCOLOGICA TURCICA, 49(3), 237 - 242. |
| Chicago | SEBER SELCUK,Solmaz Dilek,YETİŞYİĞİT Tarkan Serum Tumor Marker Levels in Rheumatoid Arthritis. ACTA ONCOLOGICA TURCICA 49, no.3 (2016): 237 - 242. |
| MLA | SEBER SELCUK,Solmaz Dilek,YETİŞYİĞİT Tarkan Serum Tumor Marker Levels in Rheumatoid Arthritis. ACTA ONCOLOGICA TURCICA, vol.49, no.3, 2016, ss.237 - 242. |
| AMA | SEBER S,Solmaz D,YETİŞYİĞİT T Serum Tumor Marker Levels in Rheumatoid Arthritis. ACTA ONCOLOGICA TURCICA. 2016; 49(3): 237 - 242. |
| Vancouver | SEBER S,Solmaz D,YETİŞYİĞİT T Serum Tumor Marker Levels in Rheumatoid Arthritis. ACTA ONCOLOGICA TURCICA. 2016; 49(3): 237 - 242. |
| IEEE | SEBER S,Solmaz D,YETİŞYİĞİT T "Serum Tumor Marker Levels in Rheumatoid Arthritis." ACTA ONCOLOGICA TURCICA, 49, ss.237 - 242, 2016. |
| ISNAD | SEBER, SELCUK vd. "Serum Tumor Marker Levels in Rheumatoid Arthritis". ACTA ONCOLOGICA TURCICA 49/3 (2016), 237-242. |
